Matches in SemOpenAlex for { <https://semopenalex.org/work/W4237156473> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4237156473 endingPage "130776" @default.
- W4237156473 startingPage "130776" @default.
- W4237156473 abstract "Purpose To predict survival in patients with metastatic melanoma by evaluating a combination of serum lactate dehydrogenase (LDH) level and initial computed tomographic (CT) findings of tumor devascularization after antiangiogenic therapy. Materials and Methods Consent was waived for this institutional review board–approved, retrospective, secondary analysis. Forty-four patients with metastatic melanoma received bevacizumab therapy in a randomized prospective phase II trial. Target lesions on the initial posttherapy CT images were evaluated by using Response Evaluation Criteria in Solid Tumors, the Choi criteria, and Morphology, Attenuation, Size, and Structure (MASS) criteria. Cox proportional hazards models were used to assess the association of baseline clinical variables including serum LDH and imaging findings with progression-free and overall survival. The receiver operating characteristic curve with area under the curve (AUC) was used to evaluate accuracy. Results In multivariate analysis, a high baseline serum LDH level was associated with decreased progression-free survival (hazard ratio = 1.29 for each increase of 100 IU/L; P = .002) and overall survival (hazard ratio = 1.44 for each increase of 100 IU/L; P = .001). Evaluation with MASS criteria of the first CT examination after therapy strongly predicted progression-free (P < .001) and overall (P < .001) survival. Baseline serum LDH level was moderately accurate for predicting progression-free survival at 9 months (AUC = 0.793) and overall survival at 18 months (AUC = 0.689). The combination of baseline serum LDH levels and evaluation with MASS criteria at the first CT examination after therapy had significantly higher accuracy for predicting progression-free survival at 9 months (AUC = 0.969) and overall survival at 18 months (AUC = 0.813) than did baseline serum LDH levels alone for prediction of progression-free survival (P = .020). Conclusion A combination of baseline serum LDH levels and evaluation with MASS criteria at the first CT examination after bevacizumab therapy had the highest accuracy for predicting survival in patients with metastatic melanoma. © RSNA, 2013 Online supplemental material is available for this article." @default.
- W4237156473 created "2022-05-12" @default.
- W4237156473 creator A5003989600 @default.
- W4237156473 creator A5007950766 @default.
- W4237156473 creator A5034401006 @default.
- W4237156473 creator A5060897770 @default.
- W4237156473 creator A5061353772 @default.
- W4237156473 creator A5073568638 @default.
- W4237156473 creator A5081220636 @default.
- W4237156473 date "2013-10-28" @default.
- W4237156473 modified "2023-09-28" @default.
- W4237156473 title "Metastatic Melanoma: Lactate Dehydrogenase Levels and CT Imaging Findings of Tumor Devascularization Allow Accurate Prediction of Survival in Patients Treated with Bevacizumab" @default.
- W4237156473 doi "https://doi.org/10.1148/radiology.13130776" @default.
- W4237156473 hasPublicationYear "2013" @default.
- W4237156473 type Work @default.
- W4237156473 citedByCount "0" @default.
- W4237156473 crossrefType "journal-article" @default.
- W4237156473 hasAuthorship W4237156473A5003989600 @default.
- W4237156473 hasAuthorship W4237156473A5007950766 @default.
- W4237156473 hasAuthorship W4237156473A5034401006 @default.
- W4237156473 hasAuthorship W4237156473A5060897770 @default.
- W4237156473 hasAuthorship W4237156473A5061353772 @default.
- W4237156473 hasAuthorship W4237156473A5073568638 @default.
- W4237156473 hasAuthorship W4237156473A5081220636 @default.
- W4237156473 hasBestOaLocation W42371564731 @default.
- W4237156473 hasConcept C10515644 @default.
- W4237156473 hasConcept C126322002 @default.
- W4237156473 hasConcept C143998085 @default.
- W4237156473 hasConcept C181199279 @default.
- W4237156473 hasConcept C185592680 @default.
- W4237156473 hasConcept C207103383 @default.
- W4237156473 hasConcept C2776694085 @default.
- W4237156473 hasConcept C2777318727 @default.
- W4237156473 hasConcept C2777802072 @default.
- W4237156473 hasConcept C2779984678 @default.
- W4237156473 hasConcept C2780739268 @default.
- W4237156473 hasConcept C2989005 @default.
- W4237156473 hasConcept C3019894029 @default.
- W4237156473 hasConcept C31760486 @default.
- W4237156473 hasConcept C44249647 @default.
- W4237156473 hasConcept C50382708 @default.
- W4237156473 hasConcept C55493867 @default.
- W4237156473 hasConcept C58471807 @default.
- W4237156473 hasConcept C71924100 @default.
- W4237156473 hasConcept C76318530 @default.
- W4237156473 hasConceptScore W4237156473C10515644 @default.
- W4237156473 hasConceptScore W4237156473C126322002 @default.
- W4237156473 hasConceptScore W4237156473C143998085 @default.
- W4237156473 hasConceptScore W4237156473C181199279 @default.
- W4237156473 hasConceptScore W4237156473C185592680 @default.
- W4237156473 hasConceptScore W4237156473C207103383 @default.
- W4237156473 hasConceptScore W4237156473C2776694085 @default.
- W4237156473 hasConceptScore W4237156473C2777318727 @default.
- W4237156473 hasConceptScore W4237156473C2777802072 @default.
- W4237156473 hasConceptScore W4237156473C2779984678 @default.
- W4237156473 hasConceptScore W4237156473C2780739268 @default.
- W4237156473 hasConceptScore W4237156473C2989005 @default.
- W4237156473 hasConceptScore W4237156473C3019894029 @default.
- W4237156473 hasConceptScore W4237156473C31760486 @default.
- W4237156473 hasConceptScore W4237156473C44249647 @default.
- W4237156473 hasConceptScore W4237156473C50382708 @default.
- W4237156473 hasConceptScore W4237156473C55493867 @default.
- W4237156473 hasConceptScore W4237156473C58471807 @default.
- W4237156473 hasConceptScore W4237156473C71924100 @default.
- W4237156473 hasConceptScore W4237156473C76318530 @default.
- W4237156473 hasLocation W42371564731 @default.
- W4237156473 hasLocation W42371564732 @default.
- W4237156473 hasOpenAccess W4237156473 @default.
- W4237156473 hasPrimaryLocation W42371564731 @default.
- W4237156473 hasRelatedWork W2152737868 @default.
- W4237156473 hasRelatedWork W2163334309 @default.
- W4237156473 hasRelatedWork W2558534037 @default.
- W4237156473 hasRelatedWork W2893495784 @default.
- W4237156473 hasRelatedWork W2921296914 @default.
- W4237156473 hasRelatedWork W2945363082 @default.
- W4237156473 hasRelatedWork W3004966710 @default.
- W4237156473 hasRelatedWork W3041757410 @default.
- W4237156473 hasRelatedWork W4237156473 @default.
- W4237156473 hasRelatedWork W4321205443 @default.
- W4237156473 isParatext "false" @default.
- W4237156473 isRetracted "false" @default.
- W4237156473 workType "article" @default.